TYK2 and keratoconus: Combining our observations from both IL-4 + IL-13- or IL-22-treated KC suggests that a topical JAK1 and TYK2 inhibitor applied to AD skin may have the highest likelihood of reducing the development of disseminated cutaneous viral infections.